Islet-like clusters derived from skeletal muscle-derived stem/progenitor cells for autologous transplantation to control type 1 diabetes in mice

Lan, Kuo‐Cheng; Chen, Shyh-Jye; Yen, Yuan-Peng; Yang, Rong‐Sen; Liu, Shing‐Hwa; Chan, Ding‐Cheng

doi:10.1080/21691401.2018.1492421

Cited by 7 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, progenitor cells from outside of the pancreas, such as murine skeletal muscle-derived progenitor cells, have been differentiated into insulin-producing clusters by a differentiation protocol comprising four steps of culture. These progenitor cells transformed into mature β-cells during development and significantly reduced hyperglycemia and improved survival after transplantation into STZ-induced diabetic mice ( 167 ). Moreover, Yi Arial Zeng’s team identified a new population of protein C receptor-positive (Procr+) endocrine progenitor cells by single-cell RNA sequencing and that did not express known endocrine or exocrine differentiation markers of the adult mouse pancreas ( 168 ).…”

Section: Pancreatic Progenitor Cell As Another Resource Of β-Cellsmentioning

confidence: 99%

Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?

Zhang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Diabetes is a metabolic disease characterized by insulin deficiency. Bioengineering of stem cells with the aim to restore insulin production and glucose regulation has the potential to cure diabetic patients. In this review, we focus on the recent developments for bioengineering of induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and pancreatic progenitor cells in view of generating insulin producing and glucose regulating cells for β-cell replacement therapies. Recent clinical trials using islet cells derived from stem cells have been initiated for the transplantation into diabetic patients, with crucial bottlenecks of tumorigenesis, post-transplant survival, genetic instability, and immunogenicity that should be further optimized. As a new approach given high expectations, bioengineered islets from stem cells occupies considerable potential for the future clinical application and addressing the treatment dilemma of diabetes.

show abstract

Section: Pancreatic Progenitor Cell As Another Resource Of β-Cellsmentioning

confidence: 99%

Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?

Zhang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…These issues led to interest in the use of Muscle-Derived Stem/Progenitor Cells (MDSPCs), which exist in skeletal muscle and have the capacity for long-term proliferation, are resistant to oxidative and inflammatory stress, and show multilineage differentiation potential [147]. To investigate the therapeutic potential of autologous MDSPCs transplantation for T1D, Lan et al applied a four-stage MDSPC differentiation protocol to generate IPCs in vitro and injected them into diabetic mice: these β-cell-like-cells effectively improved hyperglycemia and glucose intolerance and increased the survival rate in diabetic mice without the use of immunosuppressants [148].…”

Section: Mesenchymal Stem Cells (Mscs)mentioning

confidence: 99%

Latest Therapies for Type 1 Diabetes: Exsisting Setup and “Post-Insulin” Standpoints

Akil¹,

Al-Maraghi²,

Yassin³

et al. 2020

Preprint

View full text Add to dashboard Cite

Type 1 diabetes affects millions of people globally and requires careful management to avoid serious long-term complications, including heart and kidney disease, stroke, and loss of sight. The present standard-of-care for type 1 diabetes is exogenic insulin substitutional therapy. The most advanced stretegies in this area is the development of hybrid-closed loop system and the producing of long-acting insulins. Progresses in stem cell therapies have started to revolutionize the care of patients with type 1 diabetes; however, significant challenges remain including the limited islets availability, difficulties in maintaining the viability, the heterogeneity within a complex pathology and in patients’ responses to treatment. On the way, a considerable amount of efforts in maximizing the islet transplantation effectiveness by controlling the advantageous of different stem cell approaches. With the availability and the use of big data, the concept of precision medicine is gaining wide attention worldwide and could bring the dream of “presonlaized” therapies as a reality in the near future. Here we review the current range of treatments available as well as recent pre-clinical breakthroughs in the field of personlaized medicine for type 1 diabetes.

show abstract

“…Mitutsova et al indicated that MDSCs can differentiate into IPCs in pancreatic islets [6]. Lan et al [7] also confirmed that muscle-derived stem/progenitor cells are capable of differentiating into insulin-producing clusters. However, the underlying mechanisms of MDSCs differentiation into IPCs have not been fully characterized.…”

Section: Introductionmentioning

confidence: 96%

Differentially expressed microRNAs during the differentiation of muscle-derived stem cells into insulin-producing cells, a promoting role of microRNA-708-5p/STK4 axis

et al. 2022

View full text Add to dashboard Cite

Objective Stem cell therapy is a promising approach for diabetes via promoting the differentiation of insulin-producing cells (IPCs). This study aimed to screen the differentially expressed miRNAs (DEmiRNAs) during the differentiation of muscle-derived stem cells (MDSCs) into IPCs, and uncover the underlying function and mechanism of a specific DEmiRNA, miR-708-5p. Methods MDSCs were successfully isolated from the leg muscle of rats, and were induced for IPCs differentiation through a five-stage protocol. miRNA microarray assay was performed for screening DEmiRNAs during differentiation. The features of MDSCs-derived IPCs were identified by qRT-PCR, flow cytometry, and immunofluorescence staining. The targeting of STK4 by miR-708-5p was examined by luciferase assay. The protein expression of STK4, YAP1, and p-YAP1 was determined by Western blot and immunofluorescence staining. Results MDSCs were successfully isolated and differentiated into IPCs. A total of 12 common DEmiRNAs were obtained during five-stage differentiation. Among them, miR-708-5p that highly expressed in MDSCs-derived IPCs was selected. Overexpression of miR-708-5p upregulated some key transcription factors (Pdx1, Ngn3, Nkx2.2, Nkx6.1, Gata4, Gata6, Pax4, and Pax6) involving in IPCs differentiation, and increased insulin positive cells. In addition, STK4 was identified as the target gene of miR-708-5p. miR-708-5p overexpression downregulated the expression of STK4 and the downstream phosphorylated YAP1. Conclusions There were 12 DEmiRNAs involved in the differentiation of MDSCs into IPCs. miR-708-5p promoted MDSCs differentiation into IPCs probably by targeting STK4-mediated Hippo-YAP1 signaling pathway.

show abstract

Islet-like clusters derived from skeletal muscle-derived stem/progenitor cells for autologous transplantation to control type 1 diabetes in mice

Cited by 7 publications

References 39 publications

Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?

Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?

Latest Therapies for Type 1 Diabetes: Exsisting Setup and “Post-Insulin” Standpoints

Differentially expressed microRNAs during the differentiation of muscle-derived stem cells into insulin-producing cells, a promoting role of microRNA-708-5p/STK4 axis

Contact Info

Product

Resources

About